ArticleRSC medicinal chemistry2022
Target 2035 - update on the quest for a probe for every protein.
Open access · hybridAbstract readEditorial
In one paragraph
Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research.Nature communications · 2023Pooled it
- Mapping the functional dark proteome in cancer.Nature reviews. Cancer · 2026Review
- New hit compounds againstAntimicrobial agents and chemotherapy · 2026Article
- Developments and challenges in hit progression within fragment-based drug discovery.Nature communications · 2026Review
- Exploration of schizophrenia-associated gene modules using graph theory, co-expression networks, and dimensionality reduction.PloS one · 2026Article
- Enantioselective protein affinity selection mass spectrometry (E-ASMS).Nature communications · 2025Article
- High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024.ACS pharmacology & translational science · 2025Review
- Advances in sulfonyl exchange chemical biology: expanding druggable target space.Chemical science · 2025Review
- MAST Kinases' Function and Regulation: Insights from Structural Modeling and Disease Mutations.Biomedicines · 2025Article
- Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.RSC medicinal chemistry · 2025Article
- A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.Journal of medicinal chemistry · 2025Article
- Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics.Nature communications · 2025Article
- Probe my Pathway (PmP): a portal to explore the chemical coverage of the human Reactome.Database : the journal of biological databases and curation · 2024Article
- Article
- A Comprehensive Collection of Pain and Opioid Use Disorder Compounds for High-Throughput Screening and Artificial Intelligence-Driven Drug Discovery.ACS pharmacology & translational science · 2024Article
- tracerDB: a crowdsourced fluorescent tracer database for target engagement analysis.Nature communications · 2024Article
- Chemogenomics for NR1 nuclear hormone receptors.Nature communications · 2024Article
- Article
- The Pan-Canadian Chemical Library: A Mechanism to Open Academic Chemistry to High-Throughput Virtual Screening.Scientific data · 2024Article
- Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors.Nature chemical biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors at 18 institutions in 12 countries.
Susanne MüllerInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.ORCID https://orcid.org/0000-0003-2402-4157
Suzanne AcklooStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.
Arij Al ChawafUniversity of Toronto Toronto Ontario M5G 1L7 Canada.
Bissan Al-LazikaniDepartment of Data Science, The Institute of Cancer Research London SM2 5NG UK.
Albert AntolinDepartment of Data Science, The Institute of Cancer Research London SM2 5NG UK.
Jonathan B BaellMonash Institute of Pharmaceutical Sciences, Monash University Parkville Victoria 3052 Australia.ORCID https://orcid.org/0000-0003-2114-8242
Hartmut BeckResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.
Shaunna BeedieCentre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.
Ulrich A K BetzMerck KGaA Darmstadt Germany.
Gustavo Arruda BezerraCentre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.
Paul E BrennanAlzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, University of Oxford Oxford OX3 7FZ UK.ORCID https://orcid.org/0000-0002-8950-7646
David BrownInstitut Recherches de Servier 125 Chemin de Ronde 78290 Croissy France.
Peter J BrownStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.
Alex N BullockCentre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.
Adrian J CarterDiscovery Research, Boehringer Ingelheim 55216 Ingelheim am Rhein Germany.
Apirat ChaikuadInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.
Mathilde ChaineauEarly Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital, McGill University Montreal QC Canada.ORCID https://orcid.org/0000-0002-9705-0754
Alessio CiulliSchool of Life Sciences, Division of Biological Chemistry and Drug Discovery, University of Dundee James Black Centre Dundee UK.ORCID https://orcid.org/0000-0002-8654-1670
Ian CollinsCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research London SM2 5NG UK.
Jan DreherResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.
David DrewryStructural Genomics Consortium, UNC Eshelman School of Pharmacy Chapel Hill NC USA.
Kristina EdfeldtStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden.
Aled M EdwardsStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.
Ursula EgnerNuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany.
Stephen V FryeLineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA.
Stephen M FuchsInstitute for Protein Innovation Boston MA USA.
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health Rockville Maryland 20850 USA.
Ingo V HartungMedicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany.ORCID https://orcid.org/0000-0001-8750-679X
Alexander HillischResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.
Stephen H HitchcockTakeda California 9625 Towne Centre Drive San Diego California 92121 USA.
Evert HomanScience for Life Laboratory, Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.
Natarajan KannanInstitute of Bioinformatics and Department of Biochemistry and Molecular Biology, University of Georgia Athens GA USA.
James R KieferGenentech, Inc. 1 DNA Way South San Francisco California 94080 USA.
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.
Milka KosticDepartment of Cancer Biology and Chemical Biology Program, Dana-Farber Cancer Institute 450 Brookline Ave Boston MA 02215 USA.ORCID https://orcid.org/0000-0002-7003-2812
Stefan KubicekCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.
Andrew R LeachEuropean Molecular Biology Laboratory, European Bioinformatics Institute Wellcome Genome Campus, Hinxton Cambridgeshire CB10 1SD UK.
Sven LindemannStrategic Innovation, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany.ORCID https://orcid.org/0000-0002-0885-6175
Brian D MarsdenCentre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.
Hisanori MatsuiNeuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan.
Jordan L MeierChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health Frederick MD USA.ORCID https://orcid.org/0000-0002-0537-7101
Daniel MerkInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.
Maurice MichelScience for Life Laboratory, Department of Oncology-Pathology Karolinska Institutet Stockholm Sweden.
Maxwell R MorganStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-4784-6113
Anke Mueller-FahrnowNuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany.
Dafydd R OwenDiscovery Network Group, Pfizer Medicine Design Cambridge MA 02139 USA.
Benjamin G PerryDrugs for Neglected Diseases initiative 15 Chemin Camille Vidart Geneva 1202 Switzerland.ORCID https://orcid.org/0000-0001-6715-4213
Saul H RosenbergAbbVie North Chicago Illinois USA.
Kumar Singh SaikatenduGlobal Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.
Cora ScholtenResearch and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany.
Sujata SharmaStructural & Protein Sciences, Discovery Sciences, Janssen Research & Development 1400 McKean Rd Spring House PA 19477 USA.
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health Rockville Maryland 20850 USA.
Michael SundströmDivision of Rheumatology, Department of Medicine Solna, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden.
Giulio Superti-FurgaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.
Matthew H ToddSchool of Pharmacy, University College London London WC1N 1AX UK.ORCID https://orcid.org/0000-0001-7096-4751
Claudia TredupInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany.
Masoud VedadiStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-0574-0169
Frank von DelftCentre for Medicines Discovery, University of Oxford Old Road Campus Research Building, Roosevelt Drive Oxford OX3 7DQ UK.
Timothy M WillsonLineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA.
Georg E WinterCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria.
Paul WorkmanCRUK ICR/Imperial Convergence Science Centre London SM2 5NG UK.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada Cheryl.Arrowsmith@uhnresearch.ca.
Goethe University Frankfurt · DEUniversity of Toronto · CAInstitute of Cancer Research · GBUniversity of North Carolina at Chapel Hill · USUniversity of Oxford · GBBayer (Germany) · DENational Institutes of Health · USMerck (Germany) · DENanjing Tech University · CNNuvisan (Germany) · DEBoehringer Ingelheim (Germany) · DEEuropean Bioinformatics Institute · GBInstitute for Protein Innovation · USKarolinska University Hospital · SEMontreal Neurological Institute and Hospital · CAServier (France) · FRTakeda (United States) · USUniversity of Dundee · GB
Funding
Targeting Cancer Through Modifications and MetabolismZIABC011488 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MEIER, JORDAN L · 2013 to 2025
$21.3MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6MCancer Research UK 22897NCI NIH HHS T32 CA236754Wellcome Trust 204735/Z/16/Z
Abstract
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines is that proteins, and not genes, are the primary executers of biological function. Therefore, much of how biology works in health and disease must be understood through the lens of protein function. Accordingly, a subset of human proteins has been at the heart of research interests of scientists over the centuries, and we have accumulated varying degrees of knowledge about approximately 65% of the human proteome. Nevertheless, a large proportion of proteins in the human proteome (∼35%) remains uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. Target 2035 is an international federation of biomedical scientists from the public and private sectors, which aims to address this gap by developing and applying new technologies to create by year 2035 chemogenomic libraries, chemical probes, and/or biological probes for the entire human proteome.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.